Remicade (infliximab) denied due to quantity / dose limits by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## UnitedHealthcare Quantity-Limit Denials on Remicade (infliximab): The Dose-Escalation Trap

Quantity-limit (QL) denials on Remicade under UHC's commercial Medical Benefit Drug Policy (effective 02.01.2026, billing codes J1745, Q5103, Q5104, Q5121) almost always trace to one of three mechanics: (1) FDA-label dosing ceilings hard-coded into the policy, (2) UHC's biosimilar preferencing that pushes you onto Inflectra/Avsola before approving any Remicade units at all, and (3) infusion-interval shortening (every-4-week vs. every-8-week) that exceeds the labeled maintenance dose. Because Remicade is buy-and-bill medical benefit (not Optum Rx specialty pharmacy), the PA is adjudicated by UHC commercial medical review — not OptumRx — and the QL is enforced against the J1745/Q-code units per infusion event, computed against the patient's documented weight.

The most defensible appeal posture is therapeutic drug monitoring (TDM). For Crohn's and UC, ACG and AGA both endorse reactive TDM and dose intensification to 10 mg/kg or q4-week intervals when trough infliximab levels are subtherapeutic (typically <5 µg/mL for IBD, <7 µg/mL for perianal disease) without high-titer anti-drug antibodies. UHC's own policy permits "FDA-labeled dosing for the indication," and the Remicade label expressly authorizes escalation to 10 mg/kg in Crohn's and UC patients who lose response — making the QL denial internally inconsistent with the policy's own dosing clause. Submit the trough/ATI panel, body-weight documentation, and a calculated mg/kg target as Exhibit A.

If the QL denial is layered on top of the biosimilar step (UHC requires 14 weeks of Inflectra or Avsola or a physician attestation of expected superior response with Remicade), invoke 29 USC §1185d for a step-therapy override based on contraindication, prior failure, or stability on current therapy. ERISA-governed plans must produce the specific clinical rationale and any internal dosing tables under 29 CFR §2560.503-1(g) — demand them. If the plan refuses, that's an adverse benefit determination defect appealable to the IRO and reportable to the DOL EBSA.

For self-insured ERISA plans, Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) confirms the insurer carries the burden of showing the QL is medically justified — not the patient. For fully-insured plans, file simultaneously with your state DOI; UHC commercial QL denials are frequently overturned at external review when TDM data and weight-based mg/kg math are in the file.

Tactical tip: Always attach a one-page "dose justification worksheet" — current weight in kg, target mg/kg, trough level, ATI status, and the exact Remicade label section authorizing the escalation. UHC reviewers approve QL exceptions far more often when the math is done for them than when they have to compute it from a narrative letter.